A Detailed Comparative Assessment of Two Treatment Procedures (Standard Selective Serotonin Reuptake Inhibitors and Rapid-Acting Therapies/Specifically Ketamine) For Patients Suffering from Treatment-Resistant Depression Along with Evaluating the Effectiveness of These Approaches in Alleviating Symptoms and Improving Patient Outcomes: An Original Research Study

Aim: This study aims to compare two treatment procedures (standard selective serotonin reuptake inhibitors and rapid-acting therapies/specifically ketamine) for patients suffering from treatment-resistant depression along with evaluating the effectiveness of these approaches in alleviating symptoms and improving patient outcomes.

Materials and Methods: This study examined 80 patients suffering from severe sadness, hopelessness, and emotional numbness. Of these, 60 patients (ages 18 to 51) were diagnosed with treatment-resistant depression after failing to achieve satisfactory results with at least two antidepressant trials. Eligible participants had a documented diagnosis of Major Depressive Disorder or bipolar disorder, demonstrating insufficient clinical progress despite adequate treatment for a minimum of 6 to 8 weeks. The final cohort of 60 patients was divided into two groups: Group 1 received standard treatment with selective serotonin reuptake inhibitors (SSRIs), while Group 2 explored rapidacting therapies, specifically ketamine. The intention was to compare the efficacy of these two approaches in improving depressive symptoms and overall patient outcomes, offering insights into potential treatment advantages for those with treatment-resistant depression. Statistical Analysis and Results The study focused on a diverse cohort of 60 patients aged 18 to 51, all diagnosed with treatment-resistant depression. Group 1 received selective serotonin reuptake inhibitors (SSRIs), while Group 2 was treated with innovative rapid-acting therapies, particularly ketamine. A comparative analysis assessed treatment efficacy using metrics related to Quality of Life, evaluated through the Pearson Chi-Square test. Group 1's findings (n=30) showed a total score of 19 across various factors, while Group 2 (also n=30) demonstrated higher scores in most areas. Specifically, Group 2 outperformed Group 1 in response rates, effectiveness, and onset of action, efficacy, and maintenance of effect. Lastly, authors also summarize the overall treatment effects analyzed with one-way ANOVA, highlighting the comparative effectiveness and safety of SSRIs versus ketamine in treating treatment-resistant depression.

Conclusion: This study concluded that Ketamine, including IV and intranasal esketamine, is more effective than SSRIs for quickly relieving symptoms. To sustain its benefits, it requires repeated doses, usually twice weekly for two weeks. It is primarily for patients who haven't responded to at least two previous antidepressant treatments and may cause dissociation.